



## Algeta's financial calendar 2010

**Oslo, Norway, 25 January 2010 - Algeta ASA (OSE:ALGETA), the cancer therapeutics company, announces it's financial calendar for 2010**

- 19. Feb. Presentation of the annual accounts (08:00 CET)
- 22. April General meeting
- 07. May Presentation of first quarter report (09:45 CET)
- 13. Aug. Presentation of second quarter report (09:45 CET)
- 12. Nov. Presentation of third quarter report (09:45 CET)

The presentations will be held at Hotel Continental, Oslo. Algeta reserves the right to revise the dates. The calendar is available in the report for the third quarter 2009 and on [www.algeta.com](http://www.algeta.com).

###

### For further information, please contact

Andrew Kay, CEO +47 2300 7990 / +47 4840 1360 (mob)  
Øystein Soug, CFO +47 2300 7990 / +47 9065 6525 (mob)  
[post@algeta.com](mailto:post@algeta.com)

*International media enquiries:* +44 207 638 9571  
Mark Swallow/Helena Galilee/David Dible [mark.swallow@citigatedr.co.uk](mailto:mark.swallow@citigatedr.co.uk)  
Citigate Dewe Rogerson

*US investor enquiries:* +1 646 378 2928  
Jessica Lloyd [jlloyd@troutgroup.com](mailto:jlloyd@troutgroup.com)  
The Trout Group

### **About Algeta**

*Algeta ASA is a cancer therapeutics company built on world-leading, proprietary technology. Algeta is developing a new generation of targeted cancer therapeutics (alpha-pharmaceuticals) that harness the unique characteristics of alpha particle emitters and are potent, well-tolerated and convenient to use.*

*Algeta's lead alpha-pharmaceutical candidate, Alpharadin (based on radium-223), has blockbuster potential for treating bone metastases arising from multiple major cancer types, owing to its bone-targeting nature, potent efficacy (therapeutic and palliative) and benign, placebo-like safety profile. Development of Alpharadin is most advanced targeting bone metastases resulting from hormone-refractory prostate cancer (HRPC), and it entered an international phase III clinical trial (ALSYMPCA) in mid-2008 based on*



*compelling clinical results from a comprehensive phase II program. This trial is currently open for recruitment.*

*In September 2009, Algeta entered into an global agreement with Bayer Healthcare AG for the development and commercialization of Alpharadin. As part of the agreement, Algeta retains an option to co-promote Alpharadin in the United States and to share profits from future sales.*

*Algeta is also developing other technologies for delivering alpha-pharmaceuticals. These include methods to enhance the potency of therapeutic antibodies and other tumor-targeting molecules by linking them to the alpha particle emitter thorium-227. The Company is headquartered in Oslo, Norway, and was founded in 1997. Algeta listed on the Oslo Stock Exchange in March 2007 (Ticker: ALGETA).*

*Alpharadin and Algeta are trademarks of Algeta ASA.*

**Forward-looking Statement**

*This news release contains forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on results of operations and the financial condition of Algeta. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. These factors include, among other things, risks associated with technological development, the risk that research & development will not yield new products that achieve commercial success, the impact of competition, the ability to close viable and profitable business deals, the risk of non-approval of patents not yet granted and difficulties of obtaining relevant governmental approvals for new products.*

###